Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KDM2B | Q8NHM5 | 10/20 | 0.58 |
| ▸ | BCHE | P06276 | 5/20 | 0.56 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14554032 | 0.90 | BCHE (0.66) | SMN1; SMN2BCHE | |
| SCHEMBL14217826 | 0.90 | BCHE (0.66) | SMN1; SMN2BCHE | |
| SCHEMBL22677330 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM2BBCHE | |
| SCHEMBL22675343 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM2BBCHE | |
| SCHEMBL13102175 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM2BBCHE | |
| Hydrochloric Acid SCHEMBL28558935 | 0.88 | BCHE (0.64) | SMN1; SMN2BCHE | |
| SCHEMBL7328973 | 0.88 | BCHE (0.73) | BCHE | |
| SCHEMBL31549857 | 0.87 | BCHE (0.76) | BCHE | |
| SCHEMBL31549848 | 0.87 | BCHE (0.76) | BCHE | |
| SCHEMBL31549856 | 0.87 | BCHE (0.76) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-7563894-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-07-21 | — | — | US | disclosed |
| WO-2009026276-A1 | 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026204-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-07-10 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| EP-0234011-B1 | 4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES AND 4-(HEXAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885KDM2B 838/4885BCHE 843/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885KDM2B 1066/4885BCHE 1245/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | SMN1; SMN2 4303/4885KDM2B 3060/4885BCHE 4812/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | SMN1; SMN2 4095/4885KDM2B 2947/4885BCHE 4766/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885KDM2B 838/4885BCHE 843/4885 |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885KDM2B 838/4885BCHE 843/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885KDM2B 838/4885BCHE 843/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | SMN1; SMN2 4095/4885KDM2B 2947/4885BCHE 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.